Compare PFAI & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PFAI | LTRN |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 31.5M |
| IPO Year | N/A | 2020 |
| Metric | PFAI | LTRN |
|---|---|---|
| Price | $2.62 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 6.4K | ★ 36.6K |
| Earning Date | 05-02-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $2.03 |
| 52 Week High | $4.93 | $5.74 |
| Indicator | PFAI | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 60.53 | 15.61 |
| Support Level | $2.22 | N/A |
| Resistance Level | $2.80 | $3.65 |
| Average True Range (ATR) | 0.12 | 0.24 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 82.26 | 0.96 |
Pinnacle Food Group Ltd is a provider of smart farming solutions focused on vertical and hydroponic farming. The company focuses on promoting sustainable food security by developing and building customized smart farming systems for customers based on the systematic integration of technology, hardware, and software, coupled with a full range of integrated supply and technical services. It sells hydroponic growing systems and technical support services to individual households and community groups, and is developing a hydroponic growing system for urban farms. Geographically, the company generates the majority revenue from Canada, followed by New Zealand.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.